Forte Biosciences prices $150M stock offering at $26.27/share

Forte Biosciences, a clinical-stage biopharmaceutical company, priced a public offering of its common stock at $26.27 per share on March 18, 2025, aiming to raise approximately $150 million in gross proceeds to fund the continued development of its lead therapeutic candidate for inflammatory skin diseases. The offering, managed by a syndicate of investment banks, represents a significant capital raise for the company as it advances its clinical pipeline. The capital infusion is primarily earmarked for advancing FB-401, Forte's lead live biotherapeutic product candidate for the treatment of atopic dermatitis, also known as eczema. The company is currently conducting mid-to-late-stage clinical trials, and the substantial funds will support these expensive research activities, including patient enrollment, data analysis, and regulatory engagement. This financing move is a common strategy for biotech firms that are not yet revenue-generating but require substantial capital to reach key clinical milestones that can enhance their valuation and attract potential partners. Market analysts note that the pricing of $26.27 per share reflects investor confidence in Forte's technology platform and the addressable market for its dermatological treatments. The successful completion of this offering, subject to customary closing conditions, will bolster the company's balance sheet, providing a multi-year runway to execute its clinical strategy without immediate need for further dilution. This financial maneuver occurs within a competitive biotech funding landscape, where companies must demonstrate clear scientific progress to secure capital from public markets.